ArticleVaccine2013
Protective immunity induced by immunization with a live, cultured Anaplasma marginale strain.
Article in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Review
- Recent advances in genetic systems in obligate intracellular human-pathogenic bacteria.Frontiers in cellular and infection microbiology · 2023Review
- Satisfactory breeding potential is transiently eliminated in beef bulls with clinical anaplasmosis.BMC veterinary research · 2022Article
- Targeted mutagenesis in Anaplasma marginale to define virulence and vaccine development against bovine anaplasmosis.PLoS pathogens · 2022Article
- Bovine Anaplasmosis: Will there ever be an almighty effective vaccine?Frontiers in veterinary science · 2022Review
- Failure to Eliminate PersistentVeterinary sciences · 2021Article
- Development of a subcutaneous ear implant to deliver an anaplasmosis vaccine to dairy steers.Journal of animal science · 2020Article
- Article
- Mutational analysis of gene function in the Anaplasmataceae: Challenges and perspectives.Ticks and tick-borne diseases · 2019Article
- Anaplasma marginale: Diversity, Virulence, and Vaccine Landscape through a Genomics Approach.BioMed research international · 2016Review
- Reduced Infectivity in cattle for an outer membrane protein mutant of Anaplasma marginale.Applied and environmental microbiology · 2015Article
- The Effect of Cooled Perches on Immunological Parameters of Caged White Leghorn Hens during the Hot Summer Months.PloS one · 2015Article
- Mutations in Ehrlichia chaffeensis Causing Polar Effects in Gene Expression and Differential Host Specificities.PloS one · 2015Article
- Immunization-induced Anaplasma marginale-specific T-lymphocyte responses impaired by A. marginale infection are restored after eliminating infection with tetracycline.Clinical and vaccine immunology : CVI · 2014Article
- Global transcriptional analysis reveals surface remodeling of Anaplasma marginale in the tick vector.Parasites & vectors · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite significant economic losses resulting from infection with Anaplasma marginale, a tick-transmitted rickettsial pathogen of cattle, available vaccines provide, at best, only partial protection against clinical disease. The green-fluorescent protein expressing mutant of the A. marginale St. Maries strain is a live, marked vaccine candidate (AmStM-GFP). To test whether AmStM-GFP is safe and provides clinical protection, a group of calves was vaccinated, and clinical parameters, including percent parasitized erythrocytes (PPE), packed cell volume (PCV) and days required to reach peak bacteremia, were measured following inoculation and following tick challenge with wild type St. Maries strain (AmStM). These clinical parameters were compared to those obtained during infection with the A. marginale subsp. centrale vaccine strain (A. centrale) or wild type AmStM. AmStM-GFP resulted in similar clinical parameters to A. centrale, but had a lower maximum PPE, smaller drop in PCV and took longer to reach peak bacteremia than wild type AmStM. AmStM-GFP provided clinical protection, yielding a stable PCV and low bacteremia following challenge, whereas A. centrale only afforded partial clinical protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.